Short answer
Xencor Inc (XNCR) filed an 8-K current report with the SEC on May 5, 2026 reporting Item 7.01 (Regulation FD Disclosure). Phase 1 XmAb942 results in healthy participants and preclinical XmAb412 data disclosed May 5, 2026.
Xencor Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Phase 1 XmAb942 results in healthy participants and preclinical XmAb412 data disclosed May 5, 2026
- TL1A portfolio update presented at Digestive Disease Week 2026
- Investor materials furnished as Exhibits 99.1 and 99.2, with detailed study results and pipeline information
- XmAb942 and XmAb412 data represent clinical and preclinical-stage updates, not efficacy confirmation in patients
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Xencor Inc 8-K filings
Get the next XNCR 8-K as it lands
Follow XNCR for push alerts, or ask the research agent what this filing means.